Logo image of ALSAF.PA

SAFE ORTHOPAEDICS SA (ALSAF.PA) Stock Fundamental Analysis

EPA:ALSAF - Euronext Paris - Matif - FR001400RKU0 - Common Stock - Currency: EUR

0.0024  0 (0%)

Fundamental Rating

2

ALSAF gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. ALSAF may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALSAF is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSAF has reported negative net income.
ALSAF had negative earnings in each of the past 5 years.
In the past 5 years ALSAF always reported negative operating cash flow.
ALSAF.PA Yearly Net Income VS EBIT VS OCF VS FCFALSAF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

ALSAF has a Return On Assets of -342.67%. This is amonst the worse of the industry: ALSAF underperforms 93.22% of its industry peers.
Industry RankSector Rank
ROA -342.67%
ROE N/A
ROIC N/A
ROA(3y)-117.06%
ROA(5y)-110.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSAF.PA Yearly ROA, ROE, ROICALSAF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

Looking at the Gross Margin, with a value of 74.41%, ALSAF belongs to the top of the industry, outperforming 81.36% of the companies in the same industry.
In the last couple of years the Gross Margin of ALSAF has grown nicely.
The Profit Margin and Operating Margin are not available for ALSAF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.84%
GM growth 5Y11.39%
ALSAF.PA Yearly Profit, Operating, Gross MarginsALSAF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

ALSAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALSAF has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALSAF has more shares outstanding
Compared to 1 year ago, ALSAF has a worse debt to assets ratio.
ALSAF.PA Yearly Shares OutstandingALSAF.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20K 40K 60K 80K 100K
ALSAF.PA Yearly Total Debt VS Total AssetsALSAF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -13.66, we must say that ALSAF is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -13.66, ALSAF is not doing good in the industry: 89.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.66
ROIC/WACCN/A
WACC3.69%
ALSAF.PA Yearly LT Debt VS Equity VS FCFALSAF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

2.3 Liquidity

A Current Ratio of 0.04 indicates that ALSAF may have some problems paying its short term obligations.
The Current ratio of ALSAF (0.04) is worse than 94.92% of its industry peers.
A Quick Ratio of 0.02 indicates that ALSAF may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.02, ALSAF is doing worse than 94.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.02
ALSAF.PA Yearly Current Assets VS Current LiabilitesALSAF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ALSAF have decreased by -2.53% in the last year.
ALSAF shows a decrease in Revenue. In the last year, the revenue decreased by -0.87%.
The Revenue has been growing by 10.85% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-0.87%
Revenue growth 3Y16.67%
Revenue growth 5Y10.85%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALSAF will show a very strong growth in Earnings Per Share. The EPS will grow by 22.47% on average per year.
Based on estimates for the next years, ALSAF will show a quite strong growth in Revenue. The Revenue will grow by 15.92% on average per year.
EPS Next Y41.67%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20.31%
Revenue Next 2Y15.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALSAF.PA Yearly Revenue VS EstimatesALSAF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
ALSAF.PA Yearly EPS VS EstimatesALSAF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M -500M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALSAF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSAF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSAF.PA Price Earnings VS Forward Price EarningsALSAF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSAF.PA Per share dataALSAF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10K -20K -30K -40K -50K

4.3 Compensation for Growth

ALSAF's earnings are expected to grow with 22.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALSAF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAFE ORTHOPAEDICS SA

EPA:ALSAF (6/17/2025, 7:00:00 PM)

0.0024

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)06-30 2025-06-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap186.79K
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-54931.55
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS-1.93
TBVpS-1.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -342.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.41%
FCFM N/A
ROA(3y)-117.06%
ROA(5y)-110.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.84%
GM growth 5Y11.39%
F-ScoreN/A
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.02
Altman-Z -13.66
F-ScoreN/A
WACC3.69%
ROIC/WACCN/A
Cap/Depr(3y)105.32%
Cap/Depr(5y)103.66%
Cap/Sales(3y)19.53%
Cap/Sales(5y)16.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y41.67%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.87%
Revenue growth 3Y16.67%
Revenue growth 5Y10.85%
Sales Q2Q%N/A
Revenue Next Year20.31%
Revenue Next 2Y15.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.23%
OCF growth 3YN/A
OCF growth 5YN/A